STU:GU5 (Hong Kong)
Â
Class H
€
2.44
(-1.61%)
Jun 21
Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
NAICS : 325411
ISIN : CNE100000387
Share Class Description:
STU:GU5: Class HCompare
Compare
Traded in other countries / regions
600332.China00874.Hong KongGU5.GermanyGZPHF.USA IPO Date
2010-04-01Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is active in the healthcare sector. The company manufactures pharmaceutical products including antibiotics, vasodilators, and traditional Chinese medical therapies in preparations such as injection, tablet, capsule, powder, cream, and oral liquid. Its segment includes Great Southern TCM; Great Health; Great Commerce and others. The company generates maximum revenue from the Great Commerce segment.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | 2.44 | |||||
Interest Coverage | 11.28 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.64 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | 11.5 | |||||
3-Year EPS without NRI Growth Rate | 11.4 | |||||
3-Year Book Growth Rate | 10.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 8 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.76 | |||||
9-Day RSI | 35.38 | |||||
14-Day RSI | 39.91 | |||||
6-1 Month Momentum % | 11.76 | |||||
12-1 Month Momentum % | -0.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.64 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 0.58 | |||||
Days Inventory | 57.28 | |||||
Days Sales Outstanding | 76.39 | |||||
Days Payable | 89.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 4.03 | |||||
Dividend Payout Ratio | 0.3 | |||||
3-Year Dividend Growth Rate | 7.5 | |||||
Forward Dividend Yield % | 4.03 | |||||
5-Year Yield-on-Cost % | 7.66 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 18.52 | |||||
Operating Margin % | 6.47 | |||||
Net Margin % | 5.34 | |||||
FCF Margin % | 2.76 | |||||
ROE % | 11.79 | |||||
ROA % | 5.42 | |||||
ROIC % | 12.25 | |||||
ROC (Joel Greenblatt) % | 52.11 | |||||
ROCE % | 13.45 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 11.68 | |||||
PE Ratio without NRI | 11.56 | |||||
Shiller PE Ratio | 14.91 | |||||
Price-to-Owner-Earnings | 18.06 | |||||
PEG Ratio | 1.36 | |||||
PS Ratio | 0.62 | |||||
PB Ratio | 1.3 | |||||
Price-to-Tangible-Book | 1.46 | |||||
Price-to-Free-Cash-Flow | 22.88 | |||||
Price-to-Operating-Cash-Flow | 12.6 | |||||
EV-to-EBIT | 7.04 | |||||
EV-to-EBITDA | 7.04 | |||||
EV-to-Revenue | 0.52 | |||||
EV-to-FCF | 19.01 | |||||
Price-to-Projected-FCF | 0.81 | |||||
Price-to-DCF (Earnings Based) | 0.37 | |||||
Price-to-DCF (FCF Based) | 1.26 | |||||
Price-to-Median-PS-Value | 0.47 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.36 | |||||
Price-to-Graham-Number | 0.87 | |||||
Price-to-Net-Current-Asset-Value | 3.39 | |||||
Earnings Yield (Greenblatt) % | 14.2 | |||||
FCF Yield % | 4.57 | |||||
Forward Rate of Return (Yacktman) % | 13.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 9,859.74 | ||
EPS (TTM) (€) | 0.324 | ||
Beta | 0.09 | ||
Volatility % | 21.45 | ||
14-Day RSI | 39.91 | ||
14-Day ATR (€) | 0.047714 | ||
20-Day SMA (€) | 2.572 | ||
12-1 Month Momentum % | -0.75 | ||
52-Week Range (€) | 2.12 - 2.74 | ||
Shares Outstanding (Mil) | 1,625.79 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Frequently Asked Questions
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5)'s stock price today?
The current price of STU:GU5 is €2.44. The 52 week high of STU:GU5 is €2.74 and 52 week low is €2.12.
When is next earnings date of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5)?
The next earnings date of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5) is .
Does Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5) pay dividends? If so, how much?
The Dividend Yield %  of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5) is 4.03% (As of Today), Highest Dividend Payout Ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5) was 0.36. The lowest was 0.24. And the median was 0.29. The  Forward Dividend Yield % of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(STU:GU5) is 4.03%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |